A5056030451- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- CAR-T cell therapy research
- Cancer, Lipids, and Metabolism
- Ubiquitin and proteasome pathways
- Cellular Mechanics and Interactions
- Epigenetics and DNA Methylation
- Microtubule and mitosis dynamics
- Nuclear Structure and Function
- Family Support in Illness
- Medical Imaging and Analysis
- Cancer Cells and Metastasis
- 3D Printing in Biomedical Research
- Metabolomics and Mass Spectrometry Studies
- Childhood Cancer Survivors' Quality of Life
- Caveolin-1 and cellular processes
- Biochemical and Molecular Research
- Neuroblastoma Research and Treatments
- Clusterin in disease pathology
- Cancer survivorship and care
- RNA modifications and cancer
- Radiomics and Machine Learning in Medical Imaging
- Nanowire Synthesis and Applications
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
McMaster University
2021-2024
Gene expression profiling of medulloblastoma cells undergoing therapy identifies BPIFB4 as a novel target for recurrent disease.
Medulloblastoma (MB) is the most common type of malignant pediatric brain cancer. The current standard care (SOC) involves maximal safe resection and chemoradiotherapy in individuals older than 3 years, often leading to devastating neurocognitive developmental deficits. Out four distinct molecular subgroups, Group 4 have poorest patient outcomes due aggressive nature tumor propensity metastasize recur post therapy. toxicity SOC lack response specific subtypes underscores urgent need for...
Pediatric central nervous system (CNS) tumors are the most common solid diagnosed in children and leading cause of pediatric cancer-related death. Those who do survive faced with long-term adverse effects current standard care treatments chemotherapy, radiation, surgery. There is a pressing need for novel therapeutic strategies to treat CNS more effectively while reducing toxicity - one these modalities chimeric antigen receptor (CAR) T-cell therapy. Currently approved use several...
Abstract Medulloblastoma (MB) is the most common malignant pediatric brain tumor, comprised of four distinct molecular subgroups (WNT, SHH, Group 3, and 4). A subset 3 MB tumors harbor focal amplifications MYC oncogene are particularly prone to tumor recurrence leptomeningeal spread which currently remains incurable. Therefore, there an urgent need for development therapeutic modalities that can spare vulnerable, developing while having potent antitumor efficacy against recurrent MB. Through...
<h3>Background</h3> Medulloblastoma (MB) is the most common, malignant pediatric brain tumour comprised of four distinct molecular subgroups (WNT, SHH, Group 3, and 4). A subset 3 MB tumors harbor focal amplifications <i>MYC</i> oncogene (<i>MYC</i>-G3MB) are particularly prone to recurrence leptomeningeal spread due their highly proliferative nature linked its embryonic stem cell-of-origin programing. Therefore, there an urgent need for development therapeutic modalities that safe have...
Abstract Medulloblastoma (MB) is the most common, malignant pediatric brain tumour comprised of four distinct molecular subgroups (WNT, SHH, Group 3, and 4). A subset 3 MB tumors harbors focal amplifications MYC oncogene (MYC-G3MB) are particularly prone to recurrence due their highly proliferative nature linked its embryonic stem cell-of-origin programming. We discovered that LBR, an inner nuclear transmembrane protein, while present in all cells at envelope (NE), aberrantly presented cell...
Abstract Medulloblastoma (MB) is the most common malignant pediatric brain cancer, originating from cerebellum. Despite advancements in standard of care (SoC), MB remains fatal for 30% patients. Tumor relapse, spinal metastasis and treatment resistance are prevalent MYC-driven Group 3 (G3-MB). Patients surviving SoC faced with life-long neurocognitive neurodevelopmental deficits. These issues highlight urgent need improved modalities. Reprogramming cellular lipid metabolism an emerging...
Abstract [Background] Medulloblastoma (MB) is the most frequently diagnosed malignant pediatric brain tumor. Multiple integrated genomic analyses have been used to stratify MB into four molecular subgroups, each unique in its gene expression profile, clinical characteristics, and prognosis. MYC-driven group 3 (G3MB) tumors are poorly understood entities, defined by metastasis down leptomeninges, disease recurrence particularly poor survival. There hence an urgent need for a more thorough...
Abstract Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Of its four distinct molecular subgroups, Group 3 MBs are associated with increased risk of recurrence, metastasis and overall poor patient outcome. In recent years, small molecule inhibitors that decrease BMI1 expression have shown to be efficacious against several types tumors including MB. Although in vivo studies provide a promising proof-of-concept for therapeutic targeting MB, mice receive treatment...
Abstract Medulloblastoma (MB) is the most common pediatric brain tumor comprising of four subgroups: WNT, SHH, Group 3 (Gp3) and 4 (G4). Improved Standard care has led to a greatly improved patient survival. However, 30% patients still succumb disease survivors are plagued with lifelong neuro-cognitive neuro-developmental disorders. MYC amplified G3MB highly aggressive subgroup high frequency metastasis recurrence, leading bleak prognosis. Molecular understanding lacking treatment options...
Abstract Medulloblastoma (MB) is the most common type of malignant pediatric brain cancer. Current standard care (SOC) involves maximal safe resection and neuraxis radiotherapy chemotherapy in individuals older than 3 years. To date, these cytotoxic SOC combined with craniospinal irradiation led to devastating neurocognitive developmental deficits impacting quality life for patients. The biological heterogeneity MB highlighted by existence four distinct molecular subgroups (WNT, SHH, Group...